Global Perfusion Systems Market – Growth Analysis Forecasts to 2021
The global Perfusion
Systems Market is expected to reach USD 1,198.8 Million by 2021 from USD
989.4 Million in 2016, at a CAGR of 3.9%. The growth of the market can be
attributed to the increasing prevalence of cardiovascular & respiratory
diseases, initiatives by governments & NGOs to encourage organ donation,
increasing investment in cell-based research, and developments in biologics
manufacturing. The high cost of organ transplantation and organ supply-demand
gap, however, are expected to hinder the growth of the market.
The Perfusion Systems Market is segmented
on the basis of type (namely cardiopulmonary perfusion systems, ex vivo organ perfusion
systems, and cell perfusion systems) and region.
Geographically, North America is estimated
to account for the largest share of the global market, followed by Europe. The
Asia-Pacific region is expected to witness the highest growth in the market
during the forecast period. This growth will be particularly centered on China,
Japan, and India.
The major players in the cardiopulmonary Perfusion Systems Market include
Getinge AB (Sweden), Medtronic plc (Ireland), LivaNova PLC (U.K.), Terumo
Corporation (Japan), and XENIOS AG (Germany). The major players in the ex vivo
organ perfusion system market are Lifeline Scientific, Inc. (U.S.) and XVIVO
Perfusion AB (Sweden), while, Repligen Corporation (U.S.), Spectrum
Laboratories, Inc. (U.S.), Merck KGaA (Germany), Harvard Bioscience, Inc.
(U.S.), and ALA Scientific Instruments, Inc. (U.S.) are some of the leading
players in the cell perfusion systems market.
Key players adopted strategies such as
partnerships, collaborations, joint ventures, agreements, mergers &
acquisitions, approvals, product launches, and expansions to maintain and
enhance their position in the market.
Partnerships, collaborations, joint
ventures, agreements, and mergers & acquisitions accounted for 28.6% of the
all strategic developments from 2013 to 2016. Players adopted this strategy to
strengthen their distribution networks, expand their research network, and
enhance their market reach & customer base. In 2015, Getinge AB partnered
with iMDsoft GmbH to integrate its data management systems into Getting’s
heart-lung machines, blood/gas monitors, and heater-cooler units. Similarly, in
2015, Sorin and Cyberonic merged to form LivaNova PLC. The key players that
adopted these strategies were Getinge AB, Medtronic plc, LivaNova PLC, Terumo
Corporation, and XENIOS AG.
Product launches accounted for 21.9% of strategic
developments in the market from 2013 to 2016. This strategy was employed by
players to enhance their product portfolios. In 2015, Medtronic plc launched
Affinity CP Centrifugal Blood Pump in Brazil. Similarly, LivaNova PLC launched
Flextherm— heating and cooling systems in 2015. In 2016, Terumo Corporation
launched the CAPIOX FX Advance oxygenator. Medtronic plc, LivaNova PLC,
Lifeline Scientific, Inc., XVIVO Perfusion AB, Repligen Corporation, and Terumo
Corporation were the key players who adopted this strategy.
Contact:
Mr.
Shelly Singh
MarketsandMarkets™
INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
newsletter@marketsandmarkets.com
newsletter@marketsandmarkets.com
Comments
Post a Comment